v3.23.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities:    
Net loss $ (1,367,659) $ (1,656,918)
Stock-based compensation expense included in -    
General and administrative costs 276,980 339,672
(Increase) decrease in -    
Advances on research and development contract services 15,823 3,224
Prepaid insurance (5,995) (21,072)
Other prepaid expenses and current assets (45,719) (41,670)
Increase (decrease) in -    
Accounts payable and accrued expenses (6,133) 143,525
Research and development contract liabilities (138,666) 198,142
Net cash used in operating activities (1,271,369) (1,035,097)
Cash flows from financing activities:    
Exercise of common stock options 6,281
Payment of deferred offering costs (10,906)
Net cash provided by (used in) financing activities 6,281 (10,906)
Cash:    
Net decrease (1,265,088) (1,046,003)
Balance at beginning of period 5,353,392 4,823,745
Balance at end of period 4,088,304 3,777,742
Supplemental disclosures of cash flow information:    
Interest 3,861 2,494
Income taxes

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL